Parkinson's Disease Evaluated by PET and the Effect of Memantine

Purpose of study: To investigate whether the NMDA antagonist Memantine has a substantial effect of brain metabolism in patients with Parkinson's disease (PD), using Positron Emission Tomography (PET).

Background: Disturbances in brain metabolism is thought to contribute to degeneration of neurons in brain of PD patients. Production of toxic oxygen radicals and presence of too much excitatory neurotransmitter (glutamate) due to over activity is involved. These factors can theoretically be alleviated by memantine.

Hypothesis: Memantine decreases metabolism in areas in PD brain known to be over-active. Decreases in cerebral blood flow and oxygen metabolism in these areas will be the consequence and this can be detected by PET.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson's Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

50 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

PET center, Aarhus University Hospital

Aarhus, 8000, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Parkinson's Disease (British Brain Bank Criteria)
Age 50-70y

Exclusion criteria

Tobacco use
Any serious medical conditions (Heart disease, kidney disease, liver disease, endocrinological disorders etc)
Metal implants contraindicating MR scan
Drug use affecting the central nervous system
Psychiatric disorders
Head trauma or any disorders of the head, skull or brain
Drug addiction or use of any kind of illegal substance affecting the central nervous system
Pregnancy

Treatment and study plan

memantine (drug)

Drug

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Collaborators

Lundbeck Foundation

Registry information

Official study title

Parkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist Memantine

Important dates

Study start: 2005
Study completion: 2006
First posted: Sep 13, 2006
Registry last updated: Sep 13, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed